Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06214195 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity

Study acronym: START
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
Trial Details
NCT Number NCT06214195
Lead Sponsor Zhejiang Cancer Hospital
Conditions
(from sponsor)		 Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Related terms Cardiotoxicity
Enrollment 276 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov